Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Department of Biomedical Research, National Jewish Health, Denver, CO, United States.
Front Immunol. 2019 Jan 31;10:99. doi: 10.3389/fimmu.2019.00099. eCollection 2019.
Type 1 diabetes (T1D) is a T cell mediated autoimmune disease that affects more than 19 million people with incidence increasing rapidly worldwide. For T cells to effectively drive T1D, they must first traffic to the islets and extravasate through the islet vasculature. Understanding the cues that lead to T cell entry into inflamed islets is important because diagnosed T1D patients already have established immune infiltration of their islets. Here we show that CD11c cells are a key mediator of T cell trafficking to infiltrated islets in non-obese diabetic (NOD) mice. Using intravital 2-photon islet imaging we show that T cell extravasation into the islets is an extended process, with T cells arresting in the islet vasculature in close proximity to perivascular CD11c cells. Antigen is not required for T cell trafficking to infiltrated islets, but T cell chemokine receptor signaling is necessary. Using RNAseq, we show that islet CD11c cells express over 20 different chemokines that bind chemokine receptors expressed on islet T cells. One highly expressed chemokine-receptor pair is CXCL16-CXCR6. However, NOD. CXCR6 mice progressed normally to T1D and CXCR6 deficient T cells trafficked normally to the islets. Even with CXCR3 and CXCR6 dual deficiency, T cells trafficked to infiltrated islets. These data reinforce that chemokine receptor signaling is highly redundant for T cell trafficking to inflamed islets. Importantly, depletion of CD11c cells strongly inhibited T cell trafficking to infiltrated islets of NOD mice. We suggest that targeted depletion of CD11c cells associated with the islet vasculature may yield a therapeutic target to inhibit T cell trafficking to inflamed islets to prevent progression of T1D.
1 型糖尿病(T1D)是一种 T 细胞介导的自身免疫性疾病,影响全球超过 1900 万人,发病率迅速上升。为了使 T 细胞有效地驱动 T1D,它们必须首先进入胰岛并通过胰岛血管外渗。了解导致 T 细胞进入炎症胰岛的线索非常重要,因为已确诊的 T1D 患者已经有其胰岛的免疫浸润。在这里,我们发现 CD11c 细胞是导致非肥胖型糖尿病(NOD)小鼠浸润胰岛的 T 细胞迁移的关键介质。使用活体 2 光子胰岛成像,我们发现 T 细胞进入胰岛的外渗是一个扩展过程,T 细胞在靠近血管周围 CD11c 细胞的胰岛血管中停滞。抗原不是 T 细胞浸润胰岛所必需的,但 T 细胞趋化因子受体信号是必需的。通过 RNAseq,我们发现胰岛 CD11c 细胞表达超过 20 种不同的趋化因子,这些趋化因子结合胰岛 T 细胞表达的趋化因子受体。一个高度表达的趋化因子-受体对是 CXCL16-CXCR6。然而,NOD.CXCR6 小鼠正常进展为 T1D,并且 CXCR6 缺陷型 T 细胞正常迁移到胰岛。即使存在 CXCR3 和 CXCR6 双重缺陷,T 细胞也会迁移到浸润的胰岛。这些数据强化了趋化因子受体信号对 T 细胞浸润胰岛的高度冗余性。重要的是,CD11c 细胞的耗竭强烈抑制了 NOD 小鼠浸润胰岛的 T 细胞迁移。我们建议,与胰岛血管相关的 CD11c 细胞的靶向耗竭可能为抑制 T 细胞迁移到炎症胰岛以防止 T1D 进展提供治疗靶点。